We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
-6.25%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$461M
AUM Growth
+$182M
(+65%)
Cap. Flow
+$209M
Cap. Flow
% of AUM
45.44%
Top 10 Holdings %
Top 10 Hldgs %
74.85%
Holding
54
New
8
Increased
8
Reduced
20
Closed
12
Top Buys
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$6.76M |
| 2 |
FOLD
Amicus Therapeutics
FOLD
|
+$5.63M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
+$5.61M |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
+$4.67M |
| 5 |
Axsome Therapeutics
AXSM
|
+$2.93M |
Top Sells
| 1 |
Ascendis Pharma A/S
ASND
|
+$5.79M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$5.09M |
| 3 |
CMPS
Compass Pathways
CMPS
|
+$4.64M |
| 4 |
Rocket Pharmaceuticals
RCKT
|
+$3.89M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$3.83M |
Sector Composition
| 1 | Healthcare | 43.42% |
| 2 | Financials | 0.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
| $226M | 49.01% |
+500,000
| New | +$223M |
|
2
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $27M | 5.85% |
+300,000
| New | +$27.7M |
|
|
3
Ascendis Pharma A/S
ASND
$17.1B
| $16.4M | 3.57% |
140,000
-50,000
| -26% | -$5.79M |
|
4
Cogent Biosciences
COGT
$6.68B
| $12.7M | 2.76% |
1,700,000
| – | – |
|
|
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
| $12.7M | 2.76% |
250,000
-75,000
| -23% | -$3.31M |
|
|
MRUS
6
DELISTED
Merus
MRUS
| $10.6M | 2.3% |
400,000
+50,000
| +14% | +$1.34M |
|
|
FOLD
7
DELISTED
Amicus Therapeutics
FOLD
| $10.4M | 2.26% |
1,100,000
+600,000
| +120% | +$5.63M |
|
|
SRRA
8
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $10.4M | 2.26% |
325,000
+75,000
| +30% | +$2.15M |
|
9
Celldex Therapeutics
CLDX
$2.77B
| $10.2M | 2.22% |
300,000
-50,000
| -14% | -$1.6M |
|
10
Viridian Therapeutics
VRDN
$1.99B
| $8.62M | 1.87% |
466,403
-33,597
| -7% | -$646K |
|
|
KRTX
11
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $7.61M | 1.65% |
+60,000
| New | +$6.76M |
|
|
ISEE
12
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $7.57M | 1.64% |
450,000
-175,000
| -28% | -$2.59M |
|
13
Arvinas
ARVN
$517M
| $7.4M | 1.61% |
110,000
| – | – |
|
14
Vaxcyte
PCVX
$8.12B
| $7.25M | 1.57% |
300,000
+50,000
| +20% | +$1.09M |
|
|
KZR
15
DELISTED
Kezar Life Sciences
KZR
| $6.65M | 1.44% |
40,000
+15,000
| +60% | +$2.15M |
|
|
16
PUT
Axsome Therapeutics
AXSM
$11.8B
| $6.21M | 1.35% |
+150,000
| New | +$4.65M |
|
|
CTIC
17
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $6.07M | 1.32% |
1,300,000
+100,000
| +8% | +$298K |
|
|
18
BioCryst Pharmaceuticals
BCRX
$2.36B
| $5.69M | 1.24% |
+350,000
| New | +$5.61M |
|
|
RAPT
19
DELISTED
RAPT Therapeutics
RAPT
| $5.5M | 1.19% |
31,250
-12,500
| -29% | -$2.36M |
|
|
BCYC
20
Bicycle Therapeutics
BCYC
$294M
| $4.39M | 0.95% |
+100,000
| New | +$4.67M |
|
|
21
Axsome Therapeutics
AXSM
$11.8B
| $3.91M | 0.85% |
+94,500
| New | +$2.93M |
|
22
Syndax Pharmaceuticals
SNDX
$2.02B
| $3.91M | 0.85% |
225,000
-75,000
| -25% | -$1.26M |
|
|
23
Sarepta Therapeutics
SRPT
$1.82B
| $3.91M | 0.85% |
50,000
-50,000
| -50% | -$3.83M |
|
|
VRNA
24
DELISTED
Verona Pharma
VRNA
| $3.74M | 0.81% |
750,000
| – | – |
|
25
Zentalis Pharmaceuticals
ZNTL
$364M
| $3.69M | 0.8% |
80,000
| – | – |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q1 2022 Portfolio in Review
As of Q1 2022, Ghost Tree Capital held 54 positions worth $461M, up 65% from $279M the previous quarter. Its ten largest holdings account for 75% of the portfolio.
Ghost Tree Capital deployed $209M of net new capital in Q1 2022, opening 8 new positions and adding to 8 existing holdings. Its largest new stake was Karuna Therapeutics, Inc. Common Stock: 60,000 shares worth $7.61M.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 92% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $5.79M trimmed.
- Ghost Tree Capital's largest Q1 2022 buy was Karuna Therapeutics, Inc. Common Stock: 60,000 shares worth $7.61M.
- Ghost Tree Capital added most to Amicus Therapeutics in Q1 2022, an estimated $5.63M increase.
- Ghost Tree Capital's biggest Q1 2022 reduction was Ascendis Pharma A/S, cutting an estimated $5.79M.
- Ghost Tree Capital fully exited Alnylam Pharmaceuticals in Q1 2022, selling an estimated $5.09M.
- Ghost Tree Capital's ten largest holdings make up 75% of its $461M portfolio in Q1 2022.
- Ghost Tree Capital opened 8 new positions and closed 12 in Q1 2022.
- Ghost Tree Capital's portfolio value rose 65% quarter-over-quarter to $461M.
Based on Ghost Tree Capital's 13F filing for Q1 2022, filed 16 May 2022.